The Predictive Role of ERCC1 Status in Oxaliplatin Based Neoadjuvant Therapy for Metastatic Colorectal Cancer (mCRC) to the Liver

被引：6
|
作者：
Geva, Ravit [1 ]
Shamai, Sivan [1 ]
Brazowsky, Eli [2 ]
Paoulas, Michael [2 ,3 ]
Ben-Haim, Mendi [2 ,3 ]
Johnstone, Elaine [7 ]
Alex, Beny [4 ,5 ,6 ]
Shacham-Shmueli, Einat [1 ]
机构：
[1] Tel Aviv Sourasky Med Ctr, Div Oncol, Gastrointestinal Malignancies Serv, IL-6423906 Tel Aviv, Israel
[2] Tel Aviv Sourasky Med Ctr, Dept Pathol, IL-6423906 Tel Aviv, Israel
[3] Tel Aviv Sourasky Med Ctr, Div Surg, IL-6423906 Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[5] Rambam Med Ctr, Div Oncol, Haifa, Israel
[6] Technion Israel Inst Technol, Haifa, Israel
[7] Univ Oxford, Dept Oncol, Oxford OX1 2JD, England
来源：
CANCER INVESTIGATION | 2015年 / 33卷 / 04期
关键词：
Metastatic colorectal cancer; ERCC1; Oxaliplatin; PREOPERATIVE CHEMOTHERAPY; THYMIDYLATE SYNTHASE; GENE-EXPRESSION; RESECTION; SURVIVAL; SURGERY; STEATOHEPATITIS; 5-FLUOROURACIL; INCREASE;
D O I：
10.3109/07357907.2014.998834
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Increased expression of excision repair cross-complementing 1 (ERCC1) inmCRC patients could be related to their response to Oxaliplatin based chemotherapy. We evaluated ERCC1 mRNA expression levels in primary bowel and liver metastases of 51 patients, and correlated with pathologic parameters and clinical outcomes. A significant negative correlation was detected between primary tumor ERCC1 and both the extent of clear surgicalmargins (P = 0.0011) and the percent of liver metastasis necrosis (P = 0.0167). No relationship was observed between ERCC1 expression and survival. Further study is needed to assess the promising role of ERCC1 expression as a predictive marker benefiting subgroups for Oxaliplatin.
引用
收藏
页码：89 / 97
页数：9
相关论文
共 50 条
  • [1] ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt
    Kassem, Amira B.
    Salem, Salem Eid
    Abdelrahim, Mohamed E.
    Said, Amira S. A.
    Salahuddin, Ahmad
    Hussein, Marwa Mahmoud
    Bahnassy, Abeer A.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2017, 102 (01) : 78 - 85
  • [2] Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
    Baba, H.
    Watanabe, M.
    Okabe, H.
    Miyamoto, Y.
    Sakamoto, Y.
    Baba, Y.
    Iwatsuki, M.
    Chikamoto, A.
    Beppu, T.
    BRITISH JOURNAL OF CANCER, 2012, 107 (12) : 1950 - 1955
  • [3] The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer
    Liang, Jun
    Jiang, Tao
    Yao, Ru-yong
    Liu, Zi-min
    Lv, Hong-ying
    Qi, Wei-wei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (03) : 493 - 500
  • [4] Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
    H Baba
    M Watanabe
    H Okabe
    Y Miyamoto
    Y Sakamoto
    Y Baba
    M Iwatsuki
    A Chikamoto
    T Beppu
    British Journal of Cancer, 2012, 107 : 1950 - 1955
  • [5] Biological and predictive role of ERCC1 polymorphisms in cancer
    Formica, V.
    Doldo, E.
    Antonetti, F. R.
    Nardecchia, A.
    Ferroni, P.
    Riondino, S.
    Morelli, C.
    Arkenau, H. T.
    Guadagni, F.
    Orlandi, A.
    Roselli, M.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 111 : 133 - 143
  • [6] The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer
    Jun Liang
    Tao Jiang
    Ru-yong Yao
    Zi-min Liu
    Hong-ying Lv
    Wei-wei Qi
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 493 - 500
  • [7] Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil
    Han, Jae Joon
    Baek, Sun Kyung
    Lee, Jae Jin
    Kim, Gou Young
    Kim, Si-Young
    Lee, Suk-Hwan
    CANCER RESEARCH AND TREATMENT, 2014, 46 (01): : 55 - 64
  • [8] Expression of ERCC1 and TYMS in colorectal cancer patients and the predictive value of chemotherapy efficacy
    Jiang, Hong
    Li, Baosong
    Wang, Fengxia
    Ma, Chong
    Hao, Tao
    ONCOLOGY LETTERS, 2019, 18 (02) : 1157 - 1162
  • [9] ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas
    Orlandi, A.
    Di Salvatore, M.
    Bagala, C.
    Basso, M.
    Strippoli, A.
    Plastino, F.
    Calegari, M. A.
    Cassano, A.
    Astone, A.
    Barone, C.
    JOURNAL OF CANCER, 2015, 6 (01): : 70 - 81
  • [10] ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer
    Choueiri, Michel B.
    Shen, John Paul
    Gross, Andrew M.
    Huang, Justin K.
    Ideker, Trey
    Fanta, Paul
    PLOS ONE, 2015, 10 (06):
12345